Alzamend Neuro, INC Form 4 insider transactions

Hyperscale Data, Inc. reported changes in beneficial ownership of Alzamend Neuro, Inc. common stock on July 31, 2026.

Milton C Ault Iii, a Director of Alzamend Neuro, Inc., received 7,500 shares of common stock on July 31, 2026.

Director Milton C. Ault III acquired 108,388 shares of Alzamend Neuro, Inc. common stock through Ault Lending, LLC.

Alzamend Neuro Director Milton C. Ault III sold 1,851 shares of common stock to realize tax losses, maintaining significant indirect ownership.

Alzamend Neuro Director William B. Horne sold 3,333 shares of common stock at $2.1178 per share, reducing his direct beneficial ownership to zero.

Alzamend Neuro Director Lynne Fahey McGrath sold 30 shares of common stock at $2.29 per share on October 23, 2025.

Milton C. Ault III, a director at Alzamend Neuro, Inc., reported the conversion of preferred stock into common stock and subsequent sales of common stock.

Alzamend Neuro Director Milton C. Ault III reported multiple transactions in company stock, including conversions of preferred shares and open market sales, impacting his beneficial ownership.

Alzamend Neuro Director Milton C. Ault III reported the conversion of preferred stock into common shares and subsequent sales of common stock totaling over 123,000 shares.

Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc., reported selling 79,628 shares of common stock for approximately $184,161 across three transactions in late September 2025.

Alzamend Neuro's Director and 10% owner, Milton C. Ault III, reported a net increase in common stock beneficial ownership through Ault Lending, LLC, following sales and a significant preferred stock conversion.

Alzamend Neuro Director and 10% owner Milton C. Ault III reported a sale of common stock and a conversion of preferred stock into common shares.

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported recent acquisitions and disposals of common stock, along with holdings of derivative securities.

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported the sale of 129,449 shares of common stock following the conversion of preferred stock.

Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc., reported selling a total of 44,843 shares of common stock in late July 2025.

Alzamend Neuro's Director and 10% owner, Milton C. Ault III, reported sales of common stock and conversion of preferred stock into common shares.

Director Milton C. Ault III reports selling Alzamend Neuro (ALZN) shares on May 12, 2025, through direct and indirect holdings.

Director William B. Horne reports the acquisition and disposal of Alzamend Neuro, Inc. (ALZN) common stock on March 26, 2025.

Director Milton C. Ault III reports purchasing additional shares of Alzamend Neuro, Inc. through a direct purchase and entities he controls.

David Katzoff, CFO of Alzamend Neuro, Inc., reports the acquisition of 5,000 shares of common stock at a price of $1.0096 per share on March 21, 2025.

Director William B. Horne purchased 5,000 shares of Alzamend Neuro, Inc. common stock at an average price of $0.9783 on March 20, 2025.

Director William Horne exercised stock options and purchased shares of Alzamend Neuro (ALZN) common stock on March 18, 2025.

Director Milton C. Ault III reports purchasing 5,000 shares of Alzamend Neuro, Inc. common stock at $0.962 per share.

Director Milton C. Ault III reports purchasing 100 shares of Alzamend Neuro, Inc. common stock at $0.6842 per share.

Director Milton C. Ault III reports purchasing 75 shares of Alzamend Neuro, Inc. stock at $2.75 per share on August 6, 2024.

Director Milton C. Ault III reports purchasing 25 shares of Alzamend Neuro, Inc. common stock at an average price of $3.7368 on July 31, 2024.

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported purchasing 1,000 shares and disposing of 166,865 shares of common stock on April 19, 2024.

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported purchasing 334 shares of common stock at $0.9109 per share on April 1, 2024.

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported the acquisition of 2,000 shares of common stock at a price of $1.0635 per share.

Director Milton C. Ault III reports acquiring Series B Convertible Preferred Stock and warrants of Alzamend Neuro, Inc.